Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-118

There is not going to be much news in the near term until readout in January for MSA blinded trial. In my opinion MSA is not a widespread issue and this is why it does not get much publicity. We should now start focusing on Parkinson’s which is much more widely known. I am sure that the learning through MSA trials can be translated into some sort of plan to move Parkinson’s treatment forward. An announcement around that will help share price significantly in my opinion. We need to give something to the Michael J Fox Foundation to reinvest in and move Parkinson’s trial forward. We are a bit flat footed and need to start running.